Kornimate/medical-research-clean huggingface dataset:
flaxseed intervention on metabolic syndrome

Conditions: Metabolic Syndrome X

Summary: the purpose of this study is to determine whether daily supplement of 30 grams flaxseed is effective in the treatment of metabolic syndrome (mets).

metabolic syndrome (mets), a constellation of metabolic abnormalities including central obesity, dyslipidemia, elevated blood pressure and hyperglycemia, is associated with the development of type 2 diabetes and cvd. it has become one of the major public health challenges in china due to rapidly nutrition transition and the nature of obesity epidemic. treatment of mets in china is very important for the prevention of the epidemic of its consequences (such as cvd and type 2 diabetes). compelling evidence from recent human studies has demonstrated that diet and lifestyle modifications are effective means in mets management. flaxseed is a complex food source containing high amounts of alpha-linolenic acid (ala) - an omega-3 fatty acid - as well as fiber, lignan precursors and other substances that may have an impact on our health. therefore, the aim of this study is to investigate the effect of flaxseed supplementation on the management of mets in adult chinese men and women in a randomized, controlled clinical trial. a total of 200 participants with mets (defined by ncep-atpⅲ criteria) will be randomly assigned to a flaxseed-supplemented diet (30 grams/day) or an isocaloric control diet for 12 weeks. effects of flaxseed supplementation will be evaluated by measuring metabolic profile (bmi, blood pressure, total cholesterol, triglyceride, ldl-c and hdl-c, fasting glucose and insulin, hba1c), inflammatory markers (crp and il-6), markers of endothelial function (e-selectin, icam-1 and vcam-1), and fatty acid profile.

Eligibility criteria:
inclusion criteria: * with metabolic syndrome metabolic syndrome was defined based upon the updated national cholesterol education program adult treatment panel iii criteria for asian-americans as presenting at least 3 of the following components: 1) waist circumference ≥ 90 cm for men or ≥ 80 cm for women; 2) triglycerides ≥1.7mmol/l; 3) hdl cholesterol \<1.03 for men or \<1.30 for women; 4) blood pressure ≥130/85 mmhg, or current use of antihypertentive medications; 5) fasting glucose ≥5.6mmol/l or previously diagnosed type 2 diabetes or on oral antidiabetic agents or insulin. - being able to comply with the specified feeding conditions * being able to eat flaxseeds * being between the ages of 35 and 60 years exclusion criteria: * pregnancy or lactation * use of insulin * severe kidney disease * cardiovascular diseases, stroke, cancer and psychological disorders * flaxseed allergies or frequently eating flaxseeds or sesame (\>90 grams/week) * drug or alcohol abuse.

Keywords: flaxseed lignans alpha-linolenic acid ldl cholesterol
a clinical trial to assess the effects of a mouthwash containing chlorine dioxide on oral malodor

Conditions: Halitosis

Summary: a mouthwash containing chlorine dioxide would be effective to reduce oral malodor.

a randomized, double blind, crossover, placebo-controlled clinical trial was conducted among 15 healthy male volunteers, who were divided into 2 groups: experimental or control group. in the first test phase, the subjects in the experimental group were instructed to rinse with the mouthwash containing clo2 and those in the control group with the placebo mouthwash without clo2. in the second test phase after one week washout period, same procedure was conducted with the opposite mouthwashes. oral malodor was evaluated at before rinsing, right after rinsing and follows up every 30 minutes till 4 hours with om, and the concentrations of hydrogen sulfide (h2s), methyl mercaptan (ch3sh) and dimethyl sulfide ((ch3)2s) which are the main volatile sulfur compounds (vscs) of human oral malodor were evaluated with gc.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of oral malodor * rinsing the mouthwash exclusion criteria: * oral malodor caused by foods

Keywords: chlorine dioxide mouthwash organoleptic measurements volatile sulfur compounds
decision support interventions (desi) for prostate cancer screening and treatment - study 2

Conditions: Prostate Cancer

Summary: researchers in this study will determine whether providing decision support interventions (desis) to men with low risk prostate cancer improves their decision-specific knowledge and alters their treatment decisions.

potentially eligible men (age 45 and older who have localized prostate cancer with a gleason score of 6 or less) will be identified and recruited to participate in the study before their next office visit. patients who are interested and provide informed consent will be asked to complete a brief survey about background, medical history, knowledge of prostate cancer and health-related quality of life. once the survey is completed the patient will be randomly assigned to one of 2 groups. those assigned to the "usual care" group will not receive any additional information materials as part of their participation in the study. those assigned to the "patient decision support" group will receive a dvd program that contains information about treatment choices for prostate cancer. participants will be asked to answer a brief telephone survey at 3 and 6 months from the day of their last office visit. survey questions will ask about knowledge about prostate cancer, health-related quality of life, whether or not the dvd was viewed and what treatment decision was made. research staff will also review medical records 6 months after enrollment to determine which treatment was received for prostate cancer, how many visits with health care providers were completed since enrollment and which medical services and procedures were received.

Eligibility criteria:
inclusion criteria: age 45 or older localized prostate cancer with a gleason score of 6 or less exclusion criteria: women

Keywords: prostate cancer decision support interventions (desi) comparative effectiveness research (cer)
surgical valvuloplasty for congenital mitral insufficiency

Conditions: Mitral Insufficiency; Pulmonary Arterial Hypertension

Summary: congenital mitral insufficiency is one of the most common valvular diseases in the pediatric population worldwide, carrying a high morbidity and mortality risk if not treated immediately and properly. given that mitral replacement likely increased risk of cardiac dysfunction and mitral reoperation, mitral repair is the currently preferred surgical strategy in the majority of pediatric patients with mitral insufficiency. unfortunately, previous evidences demonstrated the long-term hemodynamic alteration in response to significant mitral regurgitant might lead to a reversible or irreversible pulmonary vascular remodeling regardless of concomitant other cardiac malformations, which is associated with increased risk of morbidity and mortality following the surgery. currently available researches mainly focused the association of pulmonary vascular pressures with risk of mortality and morbidity on adult rheumatic or degenerative mitral insufficiency; however, knowledge is still lacking regarding pediatric population with congenital mitral insufficiency. the investigator wil assess the relationship between baseline spap and risk of operative morbidity and mortality.


Eligibility criteria:
inclusion criteria: * evidence of normal or preserved left ventricular systolic function (defined as left ventricular ejection fraction \[lvef\] \>50%); * native mitral regurgitation of grade moderate or greater; * with or without systemic-to-pulmonary shunting necessitating concomitant surgical repairs, regardless of pulmonary arterial pressure or pulmonary artery wedge pressure. exclusion criteria: * functional single ventricle; * rheumatic mitral diseases; * eisenmenger syndrome; * aortopathy, transposition of the great arteries, obstructions of ventricular outflow tract, malignant arrhythmias, cardiomyopathy, microbiological identification of infective endocarditis; * a history of pericardiotomy or intervention therapy.
evaluation of digital follow up of preterm infants

Conditions: Preterm Birth; Development Delay; Sensory Disorder; Growth Disorders; Family Relations

Summary: the aim is to study how a digital follow up tool can identify the preterm born children and their families who need further support or clinical interventions

this study runs a digital follow up parallel to clinical follow up, up to 2 years of corrected age of the child. it evaluates the ability of the digital follow up tool to identify the problems in growth and health, eating and feeding, neurodevelopment and parental wellbeing which require further support or interventions. this study includes all infants born under 34 weeks of gestation in turku university hospital during years 2019-2022 and those preterm children born under 32 weeks of gestation who turn to 2 years during years 2019-2021. parent satisfaction about the digital follow up tool is asked at each time point and anonymously once per year. the follow up age points are the expected day of birth, 1 month, 2 months, 4 months, 8 months, 12 months, 18 months and 24 months after the expected birth date.

Eligibility criteria:
inclusion criteria: * children born before 34 weeks fo gestation and their parents * clinical follow up at turku university hospital exclusion criteria: * parents do not speak finnish, swedish or english

Keywords: preterm infant digital follow up electronic health monitoring
the effects of a sublingual sprayable microemulsion of vitamin d on inflammatory markers in covid-19 patients

Conditions: COVID-19; Vitamin D Deficiency

Summary: this placebo-controlled five-day study will be performed on 100 hospitalized covid-19 patients with vitamin d insufficiency randomized into two groups. vitamin d in the form of a sublingual sprayable microemulsion (lyl love your life® sund3 lylmicro™) is given three times daily after breakfast, lunch, and dinner (daily dose 12,000 iu) to patients with blood vitamin d levels below 30 ng/ml. the control (placebo) group recieves a placebo spray in the same daily regimen.

this placebo-controlled five-day study will be performed on 100 hospitalized covid-19 patients with vitamin d insufficiency randomized into two groups. the aim of this study is to investigate the impact of the high dose vitamin d supplementation on laboratory markers of systemic inflammation such as crp, ferritin and il-6 in hospitalized patients with covid-19. the blood samples are analyzed at the joint laboratory of the pauls stradins clinical univesity hospital. patients with confirmed sars-cov2 infection (pcr) will be randomly divided into two groups: the intervention group receives vitamin d in the form of a sublingual sprayable microemulsion (lyl love your life® sund3 lylmicro™) of 4,000 iu three times daily after breakfast, lunch and dinner; the control group receives the same regimen of placebo spray. a total of 100 inpatients will be selected for the study. all patients will receive standard care for covid-19 and existing comorbidities (diabetes, arterial hypertension, etc) according to hospital-approved protocol. the primary outcome is defined as the change in the level of the inflammatory marker and the disease's severity. population. disease severity is defined by the blood oxygen saturation level. mild clinical manifestation is characterized by spo2≥94%, moderate 90%≤spo2\<94% and severe - spo2\<90%. age, bmi, gfr, vitamin d and covid-19 severity are considered as randomization parameters.

Eligibility criteria:
inclusion criteria: * male or female subjects aged 18 and over * vitamin d level below 30 ng/ml * positive sars-cov-2 test exclusion criteria: * patients with mental health problems, * egfr ≤30 ml/min, * vitamin d level ≥ 30 ng/ml, * pregnant women * any other illness or condition that the researcher deemed may interfere with the results * patients who refuse the studies

Keywords: covid-19 crp vitamin d insufficiency vitamin d spray
multicenter study on the efficacy of transcranial direct current stimulation (tdcs) in post-stroke motor recovery

Conditions: Stroke, Ischemic; Stroke Hemorrhagic

Summary: several previous studies have used tdcs as a neuromodulation tool, showing improvements in several diseases (lefaucheur et al., 2017). based on these observations, it is believed that the use of tdcs in combination with specific motor training may provide the opportunity to induce behavioral improvements in patients with motor deficits. as shown in previous reports brain stimulation can, in fact, interact with the intrinsic ability of the brain to "repair" damaged brain functions, increasing the involvement of compensatory functional networks and thus inducing neuroplasticity. if these low-cost, easy-to-use stimulation techniques prove to be useful in improving motor deficits with long-term effects, the current study would open up new and interesting avenues in the field of neurorehabilitation. given the potential long-lasting effects of tdcs, there is currently a growing interest in the clinical sector with the aim to reduce motor deficits in patients with brain injury. the most widely used protocols in stroke patients include the application of either anodal on the hypsilesional hemisphere or cathodal tdcs on the unaffected hemisphere (contralateral), so as to increase and decrease the excitability of the motor cortex, respectively (nitsche and paulus, 2001). the main objective of this study is to evaluate the effectiveness of transcranial direct current stimulation in enhancing the functional recovery of the upper limb of stroke patients after three weeks of neuromotor training and subsequent follow-up. the secondary objective is to evaluate the treatment effects on balance, gait, motor dexterity and disability, besides the functional recovery of the lower limb.


Eligibility criteria:
inclusion criteria: * first-ever ischemic stroke * red or white stroke * barthel index \> 90 before lesion onset exclusion criteria: * previous inborn neurological disease * previous acquired neurological disease * previous or current major psychiatric illness * epilepsy or anticonvulsant treatment * use of calcium channel blocker drugs * treatments with other technologies (robotics, fes, etc.) * neurolytic treatments with botulinum toxin

Keywords: transcranial direct current stimulation stroke rehabilitation
cumulative live birth after double stimulation protocol versus antagonist protocol for poor ovarian responders

Conditions: Infertility

Summary: to compare the difference in cumulative live birth rates within one year between double stimulations protocol and two-cycle antagonist protocol in poor ovarian responders.

the theory of multicyclic development of follicles during the menstrual cycle prompted new approaches to ovarian stimulation such as double stimulation within the same menstrual cycle, in both follicular and luteal phases. the double ovarian stimulation protocol has been proposed to optimize the number of oocytes retrieved within the shortest possible timeframe.in general, the aim of duostim is to obtain the highest number of oocytes in the shortest time, thus avoiding waste of time, which is crucial for these patients.

Eligibility criteria:
inclusion criteria: 1. women diagnosed with poseidon criteria or expected poor ovarian responder （the number of oocyte retrieval ≤9） 2. women aged ≥20 years old 3. women who are undergoing their first or second art cycles 4. women who are undergoing ivf,icsi or pgt-a cycles 5. women with the number of oocyte retrieval ≤9 after their first ovarian stimulation cycle since radomization, and the number of follicle measuring 8mm or larger ≥3 exclusion criteria: 1. women with rif or rsa 2. women diagnosed with uterine abnormalities including uterine malformations, adenomyosis, submucosal fibroids, uterine adhesions or endometrial polyps 3. women with untreated hydrosalpinx that is visible under pelvic ultrasound 4. women with chromosomal abnormalities, or women who are undergoning pgt-sr or pgt-m cycles 5. women with a history of canceled fet cycle(s) due to a thin endometrium (\<7mm) 6. man with operation to get sperm

Keywords: poseidon criteria double stimulation cummulative live birth
the expression of serum angiogenesis marker in patients presenting with hemoptysis

Conditions: Inflammatory Lung Diseases; Hemoptysis

Summary: vascular endothelial growth factor (vegf) and angiopoietin-2 (ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. while elevated serum vegf levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.


Eligibility criteria:
inclusion criteria: * patients visited samsung medical center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung exclusion criteria: * patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment

Keywords: vascular endothelial growth factor angiopoietin-2
pet guided bone marrow biopsy vs trephine bone marrow biopsy

Conditions: Lymphoma; Bone Marrow Neoplasm

Summary: newly diagnosed lymphoma patients were recruited for fdg pet/ct and pet/ct guided bone marrow biopsy. all the patients also underwent routine bone marrow sampling from the posterior superior iliac spine.

newly diagnosed patients underwent fdg pet/ct for whole-body staging. all the pet/ct images were analyzed by a qualified nuclear medicine physician. the bone marrow fdg uptake was classified as negative, focal, multifocal and diffuse marrow uptake. a pet/ct guided metabolic bone marrow sampling from the fdg avid marrow-based lesion was done. however, patients with diffuse fdg avidity or no uptake in the marrow differed for pet-guided biopsy. all the patients underwent routine trephine bone marrow sampling. bone marrow infiltration (final diagnosis) was established based on trephine bone marrow sampling and fdg pet/ct targeted bone marrow biopsy results in the present study. the results of both the biopsies were correlated with the final diagnosis.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed cases of lymphoma (both hl and nhl). 2. hypermetabolic bone marrow lesions on staging 18f-fdg pet/ct, which are accessible for biopsy. 3. aged between 18 -80 years. 4. informed consent prior to the procedure. exclusion criteria: 1. previously treated/relapsed lymphoma. 2. initiation of therapy (chemotherapy, radiation therapy) and/or hematopoietic growth factor injections before 18f-fdg pet/ct or bmtb. 3. patients who underwent a prior bmtb to evaluate the role of bmi. 4. patients with pre-existing bleeding diatheses like hemophilia, coagulopathy, inr \> 1.2 and platelet counts \< 50,000/mm3, 5. patients who refuse to provide informed consent. 6. no 18f fdg avid skeletal lesions. 7. pregnant/lactating female patients. 8. non-cooperative patients.
a study to evaluate the safety and efficacy of thr-317 for the treatment of diabetic macular oedema (dme)

Conditions: Diabetic Retinopathy; Macular Edema

Summary: this study is conducted to evaluate the safety of thr-317 when administered intravitreally and to assess the compound's efficacy in improving best-corrected visual acuity (bcva) and reducing central subfield thickness (cst) in subjects with centre-involved diabetic macular oedema (dme).


Eligibility criteria:
inclusion criteria: * male or female aged 18 years or older * type 1 or type 2 diabetes * centre-involved dme with cst ≥ 340µm on spectralis sd-oct or ≥ 320µm on non-spectralis sd oct, in the study eye * reduced vision primarily due to dme, with bcva between 72 and 23 etdrs letters read at 4 meters (20/40 and 20/320 snellen equivalent) in the study eye * anti-vascular endothelial growth factor (anti-vegf) treatment naïve study eye or poor response to prior anti-vegf treatment in the study eye * non-proliferative diabetic retinopathy, or stable proliferative diabetic retinopathy without neovacularisation at the disc * written informed consent obtained from the subject prior to screening procedures exclusion criteria: * concurrent disease in the study eye, other than dme, that could compromise bcva, require medical or surgical intervention during the study period or could confound interpretation of the results * previous treatments / procedures in the study eyes as follows, or their planned use during the thr-317 treatment period for up to 30 days after the last injection: panretinal or focal / grid laser photocoagulation \[3 months\], anti-vegf treatment \[any time for anti-vegf naïve subjects; 4 weeks for subjects with a poor response to anti-vegf treatment\], intra-ocular or peri-ocular corticosteroids \[4 months\], steroid implant \[any time\], intra-ocular surgery \[3 months\], vitrectomy \[any time\] * any active ocular / intra-ocular infection or inflammation in either eye * aphakic study eye * untreated diabetes * glycated haemoglobin a (hba1c) \> 12% * uncontrolled hypertension in the opinion of the investigator * pregnant or lactating female or female of child-bearing potential not utilising an adequate form of contraception or male of reproductive potential not utilising contraception suggesting lens / zonular instability
effect of glutamine on gastric emptying and length of parenteral nutrition in premature neonates

Conditions: Enteral Feeding

Summary: this study investigates the effects of enterally supplied glutamine on gastric emptying, intestinal transit, age of total enteral nutrition and age at the end of hospitalisation. forty neonates, aged at least 2 days and free of acute illness participate in a prospective, randomised, double-blind study. all are fed with parenteral and enteral nutrition enriched with glutamine (0.7 g/kg/per day, group 1) or isonitrogenous control (group 2). gastric emptying is analysed by sequential measure of intragastric residue by diluted polyethylene glycol (peg) 4000. intestinal transit is analysed by rouge carmin test.


Eligibility criteria:
inclusion criteria: * premature neonates aged 30-33 weeks of gestational age * aged at least 2 days and no more than 10 days * free of acute illness * written informed consent is obtained from the parent prior to enrolment. exclusion criteria: * premature infants with respiratory (fraction of inspired oxygen \[fio2\] \> 30%), or cardiovascular, liver, intestinal or acute diseases * premature infants with congenital syndrome

Keywords: glutamine premature neonate gastric emptying